A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer

Summary

To evaluate the preliminary efficacy of KA2507 (an orally active potent and selective HDAC6 inhibitor) in patients with advanced biliary tract cancer (BTC) previously treated with standard of care chemotherapy.

Timeline

Start

2020-03-05

Primary completion

2023-03

Completion

2023-10

Outcome

Outcome not reported

Stopped: “Study not progressing”

Drugs

Indications